Progenity Presents Data from Award-Winning Abstract on Novel Ingestible Lab-in-a-Capsule at American College of Gastroenterology (ACG) 2020 Virtual Annual Meeting
27 oct. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present Precision Medicine Abstracts at American College of Gastroenterology (ACG) Virtual Annual Meeting in October
09 oct. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia
01 oct. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Addition to Russell 2000® Index
18 sept. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Participate in Two Upcoming Investor Conferences
02 sept. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Commends New Recommendations from ACOG and SMFM Supporting Non-Invasive Prenatal Testing (NIPT) for All Pregnancies
21 août 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Provides Corporate Updates and Reports Second Quarter 2020 Financial Results
13 août 2020 16h01 HE
|
Progenity, Inc.
Completed initial public offering raising gross proceeds of $100M Reported 75 thousand tests in the second quarter, showing resiliency of business during COVID‑19 pandemic Signed first precision...
Progenity to Report Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
Progenity, Inc.
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices
23 juil. 2020 13h58 HE
|
Progenity, Inc.
SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company focused on providing complex molecular and specialized diagnostic tests to clinicians as well as...
![VG Life Sciences Logo](/news-release/logo/302688/0/302688.jpg?lastModified=12%2F10%2F2016%2002%3A46%3A09&size=2)
VG Life Sciences Granted Key Composition of Matter Patent
02 mars 2015 10h04 HE
|
VG Life Sciences
SANTA BARBARA, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- VG Life Sciences, Inc., (OTCQB:VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, announced that the...